Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network
This study used real-world data from the TriNetX platform to evaluate the risk of MRONJ associated with various anti-osteoporosis medications, excluding combination therapies for clarity. Our findings indicate that among the commonly used parenteral anti-resorptive agents, denosumab has been associated with the highest risk of MRONJ, followed by zoledronic acid, with ibandronate showing the lowest risk.
Authors
- Hui‐Chih Hung (ORCID: https://orcid.org/0000-0003-0180-1822)
- Jun‐Fu Lin (ORCID: https://orcid.org/0009-0006-5287-7893)
- I‐Chieh Chen (ORCID: https://orcid.org/0000-0002-8345-5304)
- Ya-Lian Deng (ORCID: https://orcid.org/0000-0002-9838-7228)
- Hsu‐Tung Lee (ORCID: https://orcid.org/0000-0002-0992-2568)
- Yi‐Ming Chen (ORCID: https://orcid.org/0000-0001-7593-3065)
- Tse‐Yu Chen (ORCID: https://orcid.org/0000-0003-3529-1867)
- Ching‐Heng Lin
Institutions
- National Chung Hsing University (TW)
- Tunghai University (TW)
- Taichung Veterans General Hospital (TW)
- University College London (GB)
Publication Details
- Journal
- Bone
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.bone.2025.117678
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00